Compare WBI & ANAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | WBI | ANAB |
|---|---|---|
| Founded | 2016 | 2005 |
| Country | United States | United States |
| Employees | 540 | N/A |
| Industry | Oilfield Services/Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 1.3B |
| IPO Year | N/A | 2015 |
| Metric | WBI | ANAB |
|---|---|---|
| Price | $31.02 | $57.99 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 8 | 12 |
| Target Price | $28.25 | ★ $71.67 |
| AVG Volume (30 Days) | ★ 846.7K | 476.8K |
| Earning Date | 05-06-2026 | 05-08-2026 |
| Dividend Yield | ★ 0.67% | N/A |
| EPS Growth | N/A | ★ 91.02 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $234,603,000.00 |
| Revenue This Year | $70.12 | N/A |
| Revenue Next Year | $17.89 | $52.14 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 157.01 |
| 52 Week Low | $18.64 | $17.11 |
| 52 Week High | $36.21 | $73.30 |
| Indicator | WBI | ANAB |
|---|---|---|
| Relative Strength Index (RSI) | 51.49 | 50.75 |
| Support Level | $28.69 | $52.32 |
| Resistance Level | $31.36 | $57.70 |
| Average True Range (ATR) | 1.66 | 2.80 |
| MACD | 0.01 | 0.83 |
| Stochastic Oscillator | 22.12 | 68.70 |
WaterBridge Infrastructure LLC is an integrated, pure-play water infrastructure company with operations predominantly in the Delaware Basin, the prolific oil and natural gas basin in North America. It operates in the produced water infrastructure network in the United States through which it provides water management solutions to oil and natural gas E&P companies under long-term contracts, which include gathering, transporting, recycling, and handling produced water. It also operates two energy waste management facilities for the disposal of non-hazardous waste resulting from oil and gas E&P activities, branded under Desert Environmental. The transportation, treatment, and handling of produced water are crucial to oil and natural gas production.
AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).